2003
An open-label, nonrandomized, single-center, prospective extension, clinical trial of booster dose schedules to assess the safety profile and immunogenicity of recombinant outer-surface protein A (OspA) Lyme disease vaccine
Schoen RT, Deshefy-Longhi T, Van-Hoecke C, Buscarino C, Fikrig E. An open-label, nonrandomized, single-center, prospective extension, clinical trial of booster dose schedules to assess the safety profile and immunogenicity of recombinant outer-surface protein A (OspA) Lyme disease vaccine. Clinical Therapeutics 2003, 25: 210-224. PMID: 12637121, DOI: 10.1016/s0149-2918(03)90027-0.Peer-Reviewed Original ResearchConceptsLyme disease vaccineFirst booster doseSecond booster doseBooster doseAdverse eventsBooster dosesPrimary seriesMonth 24Disease vaccineClinical trialsEfficacy trialsImmune responseIncidence of AEsPattern of AEsLyme diseaseMost adverse eventsGeometric mean titersTotal IgG antibodiesProportion of subjectsPositive test resultsSeroprotective levelsBooster vaccinationMonth 36Third vaccinationDiary cards
2001
Recombinant Protein-44-Based Class-Specific Enzyme-Linked Immunosorbent Assays for Serologic Diagnosis of Human Granulocytic Ehrlichiosis
Magnarelli L, IJdo J, Wu C, Fikrig E. Recombinant Protein-44-Based Class-Specific Enzyme-Linked Immunosorbent Assays for Serologic Diagnosis of Human Granulocytic Ehrlichiosis. European Journal Of Clinical Microbiology & Infectious Diseases 2001, 20: 482-485. PMID: 11561804, DOI: 10.1007/s100960100542.Peer-Reviewed Original ResearchConceptsPolyvalent enzyme-linked immunosorbent assaysClass-specific enzyme-linked immunosorbent assaysEnzyme-linked immunosorbent assayIndirect fluorescent-antibody analysisFluorescent antibody analysisImmunosorbent assaySpecificity testsIgG antibodiesHigh sensitivityHuman granulocytic ehrlichiosisHuman serumGranulocytic ehrlichiosisWhole cell antigenAntibody analysisImmunoglobulin M antibodiesOnset of illnessSerologic diagnosisSerum samplesHuman granulocytic ehrlichiosis (HGE) agentPatient 3False-positive resultsIgM antibodiesM antibodiesTotal immunoglobulinTotal antibody
2000
Serologic confirmation of Ehrlichia equi and Borrelia burgdorferi infections in horses from the northeastern United States.
Magnarelli LA, Ijdo JW, Van Andel AE, Wu C, Padula SJ, Fikrig E. Serologic confirmation of Ehrlichia equi and Borrelia burgdorferi infections in horses from the northeastern United States. Journal Of The American Veterinary Medical Association 2000, 217: 1045-50. PMID: 11019714, DOI: 10.2460/javma.2000.217.1045.Peer-Reviewed Original ResearchConceptsB burgdorferiClinical signsGranulocytic ehrlichiosisSerum samplesDetectable serum antibodiesImmunoblot analysisIndirect fluorescent antibody stainingBorrelial antibodiesTick-infested areasRecombinant protein antigensProspective studyDetectable antibodiesSerum antibodiesSerologic confirmationFluorescent antibody stainingE equiAntibody reactivityClinical relevanceEtiologic agentClinical diagnosisEqui antibodiesProtein antigensEhrlichia equiELISAAntibodiesThe Emergence of Another Tickborne Infection in the 12-Town Area around Lyme, Connecticut: Human Granulocytic Ehrlichiosis
IJdo J, Meek J, Cartter M, Magnarelli L, Wu C, Tenuta S, Fikrig E, Ryder R. The Emergence of Another Tickborne Infection in the 12-Town Area around Lyme, Connecticut: Human Granulocytic Ehrlichiosis. The Journal Of Infectious Diseases 2000, 181: 1388-1393. PMID: 10751139, DOI: 10.1086/315389.Peer-Reviewed Original ResearchConceptsHuman granulocytic ehrlichiosisTickborne infectionProspective population-based surveillanceGranulocytic ehrlichiosisCommon tickborne infectionPopulation-based surveillancePrimary care providersSubset of seraIndirect fluorescent antibody methodIllness suggestiveCare providersLaboratory evidenceImportant causeProbable casesFluorescent antibody methodImmunoblot assayLyme diseaseInfectionAntibody methodIncidenceEhrlichiosisLymeMorbidityDiseaseSuggestive
1995
Safety and Immunogenicity of an Outer Surface Protein A Vaccine in Subjects with Previous Lyme Disease
Schoen R, Meurice F, Brunet C, Cretella S, Krause D, Craft J, Fikrig E. Safety and Immunogenicity of an Outer Surface Protein A Vaccine in Subjects with Previous Lyme Disease. The Journal Of Infectious Diseases 1995, 172: 1324-1329. PMID: 7594671, DOI: 10.1093/infdis/172.5.1324.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntibodies, BacterialAntibody FormationAntigens, SurfaceBacterial Outer Membrane ProteinsBacterial VaccinesBorrelia burgdorferi GroupDose-Response Relationship, DrugEnzyme-Linked Immunosorbent AssayHumansImmunization ScheduleImmunoglobulin GLipoproteinsLyme DiseaseProspective StudiesSafetyVaccines, SyntheticConceptsSide effectsLyme diseaseOspA vaccinePrevious Lyme diseaseThree-dose scheduleLocal side effectsSystemic side effectsLyme vaccineMild arthralgiaVaccine doseThird doseProspective studyOspA antibodiesHealthy volunteersOuter surface proteinsVaccinePatientsDiseaseImmunogenicityDoseMonthsSubjectsSurface proteinsSafetyArthralgia